Literature DB >> 21179604

Pharmacotherapy in Parkinson's disease: case studies.

Tiago Mestre1, Joaquim J Ferreira.   

Abstract

Parkinson's disease is a common neurodegenerative disorder with the particular feature of having various available treatments with proven efficacy. However, no treatment is curative. Recent trial results provided data for the discussion about the potential disease-modifying effect of new drugs as well as of other therapeutic strategies. The changing clinical phenotype following the progression of the disease multiplies the number of treatment targets and makes the application of recommendations from guidelines or other treatment algorithms to the individual patient a complex task. In the present manuscript, we discuss the treatment management of three case studies illustrating different stages of disease with distinct phenomenology. The proposed therapeutic alternatives are discussed based on the best data available; that is, treatment guidelines, clinical trial results or observational data.

Entities:  

Keywords:  Parkinson’s disease; case studies; guidelines; treatment

Year:  2010        PMID: 21179604      PMCID: PMC3002647          DOI: 10.1177/1756285609352366

Source DB:  PubMed          Journal:  Ther Adv Neurol Disord        ISSN: 1756-2856            Impact factor:   6.570


  31 in total

Review 1.  Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004.

Authors:  Christopher G Goetz; Werner Poewe; Olivier Rascol; Cristina Sampaio
Journal:  Mov Disord       Date:  2005-05       Impact factor: 10.338

Review 2.  Dopamine agonist monotherapy in Parkinson's disease.

Authors:  C E Clarke; M Guttman
Journal:  Lancet       Date:  2002-11-30       Impact factor: 79.321

3.  Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group.

Authors:  G Block; C Liss; S Reines; J Irr; D Nibbelink
Journal:  Eur Neurol       Date:  1997       Impact factor: 1.710

4.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

5.  Ten-year follow-up of three different initial treatments in de-novo PD: a randomized trial.

Authors:  A J Lees; R Katzenschlager; J Head; Y Ben-Shlomo
Journal:  Neurology       Date:  2001-11-13       Impact factor: 9.910

6.  Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.

Authors: 
Journal:  JAMA       Date:  2000-10-18       Impact factor: 56.272

7.  Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD.

Authors:  R Katzenschlager; J Head; A Schrag; Y Ben-Shlomo; A Evans; A J Lees
Journal:  Neurology       Date:  2008-06-25       Impact factor: 9.910

8.  Quality of life in early Parkinson's disease: impact of dyskinesias and motor fluctuations.

Authors:  Connie Marras; Anthony Lang; Murray Krahn; George Tomlinson; Gary Naglie
Journal:  Mov Disord       Date:  2004-01       Impact factor: 10.338

Review 9.  Amantadine in Parkinson's disease.

Authors:  N Crosby; K H Deane; C E Clarke
Journal:  Cochrane Database Syst Rev       Date:  2003

Review 10.  Anticholinergics for symptomatic management of Parkinson's disease.

Authors:  R Katzenschlager; C Sampaio; J Costa; A Lees
Journal:  Cochrane Database Syst Rev       Date:  2003
View more
  3 in total

1.  Real-World Evidence for a Smartwatch-Based Parkinson's Motor Assessment App for Patients Undergoing Therapy Changes.

Authors:  Aaron J Hadley; David E Riley; Dustin A Heldman
Journal:  Digit Biomark       Date:  2021-09-08

Review 2.  Deep brain stimulation for movement disorders.

Authors:  Paul S Larson
Journal:  Neurotherapeutics       Date:  2014-07       Impact factor: 7.620

3.  Dysarthria in individuals with Parkinson's disease: a protocol for a binational, cross-sectional, case-controlled study in French and European Portuguese (FraLusoPark).

Authors:  Serge Pinto; Rita Cardoso; Jasmin Sadat; Isabel Guimarães; Céline Mercier; Helena Santos; Cyril Atkinson-Clement; Joana Carvalho; Pauline Welby; Pedro Oliveira; Mariapaola D'Imperio; Sónia Frota; Alban Letanneux; Marina Vigario; Marisa Cruz; Isabel Pavão Martins; François Viallet; Joaquim J Ferreira
Journal:  BMJ Open       Date:  2016-11-17       Impact factor: 2.692

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.